Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 73763989

Next Previous
Drug Profile

JNJ 73763989

Alternative Names: ARO-HBV; JNJ-3989; JNJ-73763989

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arrowhead Pharmaceuticals
  • Developer Arrowhead Pharmaceuticals; Janssen Research & Development; Janssen Sciences Ireland UC; Johnson & Johnson Innovative Medicine
  • Class Amino sugars; Antivirals; Drug conjugates; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B; Hepatitis D

Most Recent Events

  • 13 Feb 2024 Janssen Research & Development completes a phase-II clinical trials in Hepatitis B (Treatment-naive, Combination therapy) in USA, United Kingdom, Turkey, Taiwan, Spain, Russia, Japan, France, Germany, Canada (SC) (NCT04439539) (EudraCT2019-004978-26)
  • 09 Jan 2024 Janssen completes the phase II INSIGHT trial for Hepatitis B (Combination therapy, In adults, In the elderly) in Belgium, France, Germany, Italy, New Zealand, Poland, Canada, United Kingdom and USA (SC) (EudraCT2019-004475-39) (NCT04585789)
  • 10 Nov 2023 Interim pharmacodynamics data from a phase II INSIGHT trial in Hepatitis B presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top